KOLMAR BNH Co.,Ltd. (KOSDAQ:200130)
South Korea · Delayed Price · Currency is KRW 7,740.00
-100.00 (-1.28%)
Sep 18, 2026, 3:30 PM KST
KOLMAR BNH Revenue
KOLMAR BNH had revenue of 127.23B KRW in the quarter ending June 30, 2026, a decrease of -22.47%. This brings the company's revenue in the last twelve months to 538.18B, down -8.83% year-over-year. In the year 2025, KOLMAR BNH had annual revenue of 574.88B, down -6.62%.
Revenue (ttm)
538.18B
Revenue Growth
-8.83%
P/S Ratio
0.41
Revenue / Employee
1.13B
Employees
478
Market Cap
219.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 574.88B | -40.76B | -6.62% |
| Dec 31, 2024 | 615.64B | 36.09B | 6.23% |
| Dec 31, 2023 | 579.55B | 3.65B | 0.63% |
| Dec 31, 2022 | 575.90B | -17.18B | -2.90% |
| Dec 31, 2021 | 593.08B | -13.81B | -2.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKook Pharmaceutical | 979.60B |
| Huons Global | 846.78B |
| PharmaResearch | 603.58B |
| ST Pharm | 386.46B |
| Sam Chun Dang Pharm. | 259.90B |
| BINEX | 157.28B |
| Oscotec | 144.18B |
| CG Invites | 30.11B |
KOLMAR BNH News
- 1 year ago - Kolmar BNH Revolutionizes ESG with HemoHIM, an Eco-friendly Health Supplement - Financial Post
- 1 year ago - HemoHim Manufacturer Kolmar BNH Receives NAI Classification from the US FDA - Financial Post